INEZOLID AGAINST VANCOMYCIN / CEFAZOLINE IN THE TREATMENT OF PATIENTS SUBJECTED TO HEMODIALYSIS WITH BLOODSTREAM INFECTIONS RELATED TO CATHETERS AND CAUSED BY GRAM-POSITIVE MICRORGANISMS

PFIZER S.A.,0 个研究点目标入组 0 人开始时间: 2005年7月1日最近更新: 2023年9月4日

适应症

试验速览

暂无简介。

•1. Male or female 18 years of age or older and with a body weight> 40 Kg.
•2. Patients with end-stage renal disease undergoing hemodialysis, with the following: A) Signs and symptoms of a localized infection related to catheters. B) A body temperature> 38.0 ° C or <36 ° C. C) A positive blood culture for Gram-positive microorganisms.
•3. Presence of at least one of the following systemic signs of infection: A) Hypotension. B) Tachycardia. C) Tachypnea. D) Leukocyte count> 10,000 cells / mm3 or <4,000 cells / mm3, or with a differential count showing> 10% abasted neutrophils.
•4. Patients undergoing hemodialysis with tunneled or non-tunneled catheters.
•5. Patients who are willing and able to comply with scheduled visits, plan for treatment, laboratory tests and other study procedures.

•1. Bloodstream infections related to catheters caused by Gram-negative bacteria, fungi, mixed cultures of Gram-negative bacteria and Gram-positive bacteria or mixed cultures with Gram positive / negative bacteria and fungi.
•2. Patients with evidence of other infections that result in bacteremia.
•3. Patients in whom the infected catheter can not be removed.
•4. Patients with permanent intravascular devices.
•5. Women with potential to have family who are not able or who do not wish to take adequate contraceptive precautions, who have a positive result in a test to diagnose the pregnancy within 24 hours before entering the study, that is known are pregnant, or are currently breastfeeding an infant.
•6. Identification of a pathogen resistant to linezolid or vancomycin.
•7. Patients who are unlikely to survive throughout the treatment and evaluation periods.
•8. Administration of a glycopeptide antibiotic within 5 days before enrollment.
•9. Previous enrollment in the present protocol.
•10. Hypersensitivity to linezolid, vancomycin, gentamicin or to any of its excipients.
•11. Concurrent use of another medication in research or use within 30 days of entering the study.
•12. Patients with hemodynamic compromise resistant to pressors and fluids, or with pulmonary embolism.

发起方